Evaluation of the Veriton SPECT/CT System

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04722185

Enrollment

Registered

2021-01-25

Start date

2021-01-20

Completion date

2025-12-31

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Focus of Study is Comparison of 2 Types of Gamma Cameras

Brief summary

The main purpose of this study is to evaluate a new type of gamma camera (the Veriton system) that provides a significant gain in system sensitivity and improved image quality compared to a conventional gamma camera that can achieve equal or better image quality than a standard SPECT/CT system.

Interventions

DIAGNOSTIC_TESTVeriton SPECT/CT

The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

each patient will have 2 scans - one on a conventional system and one on the newer technology

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults age 18 years or older. * Currently scheduled to undergo a nuclear medicine exam.

Exclusion criteria

* Individuals under 18 years of age. * Unwilling/unable to sign an informed consent form. * Unable to lie on a Veriton imaging table for up to 40 minutes.

Design outcomes

Primary

Measure	Time frame	Description
Image quality	1 year	Assessment of relative image quality between the Veriton system and a conventional gamma camera as a function of the type of nuclear medicine exam.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026